In the past decade, many strategies have been developed to enhance oral drug delivery. Different techniques were investigated, amongst those the use of permeation enhancers such surfactants and biodegradable polymers were studied more extensively. Chitosan derivatives have been studied as permeation enhancer in free soluble form and as nanoparticulate systems. The aim of the current work wa...

INTRODUCTION During severe sepsis or septic shock, activation of the inflammatory and coagulatory systems can result in microcirculatory dysfunction as well as microvascular thrombosis, culminating in multiple organ dysfunction and death. Enoxaparin can inhibit factor Xa and attenuate endothelial damage. The primary purpose of this study was to investigate the effect of enoxaparin on intestinal...

HEPARIN, A GLYCOSAMINOGLYCAN OF VARYING POLYsaccharide units and molecular weights, has been shown to reduce ischemic events beyond that of aspirin alone in the setting of an acute coronary syndrome (ACS). This benefit translated into a class I indication for unfractionated heparin in the 2000 American College of Cardiology/American Heart Association (ACC/ AHA) treatment guidelines for non–ST-s...

PURPOSE: To investigate the potential protective effects of enoxaparin against the adverse events of carbon dioxide (CO2) pneumoperitoneum. METHODS: Thirty four rats were divided into three groups: Group 1 (sham) underwent insertion of Veress needle into the abdomen and 90 min of anesthesia with no gas insufflation. The animals in control and enoxaparin groups were subjected to 90 min of 14 m...

BACKGROUND Cerebral vasospasm, including its ischemic sequelae, remains a leading cause of death and disability following subarachnoid hemorrhage (SAH). This study was designed to evaluate whether the low-molecular-weight heparin (LMWH) enoxaparin reduces the occurrence of cerebral vasospasm and ischemia following spontaneous SAH. METHODS A prospective, double-blind, randomized study was cond...

OBJECTIVES The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patie...

BACKGROUND AND OBJECTIVES Unfractionated heparin (UFH) and enoxaparin (low molecular weight heparin) constitute fundamental therapies in the treatment of patients with acute coronary syndrome (ACS). Since enoxaparin appears to offer clinical advantages over UFH in managing ACS, markers of thrombin generation, endothelial function and acute phase response could manifest different responses to UF...

The SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) trial is the latest in a series of landmark studies comparing the safety and efficacy of enoxaparin to unfractionated heparin (UFH) in patients with unstable angina and non–ST-segment elevation myocardial infarction. This large, multicenter, open-label study provides important...

objective: heparin and enoxaparin possess anti-inflammatory properties. we compared the effects of these drugs on inflammatory biomarkers in patients with st-segment elevated myocardial infarction (stemi). method: thirty four patients with stemi randomly separated in two groups and received standard doses of heparin and enoxaparin. the serum concentration of serum amyloid a (saa), c-reactive pr...